Durvalumab Injection 500 mg/mL – Benefits, Uses, Dosage & Side Effects

Durvalumab Injection 500 mg/mL is a prescription immunotherapy used to treat certain cancers. It is a PD-L1 immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells. It is administered by intravenous (IV) infusion under medical supervision.

Benefits of Durvalumab

Helps activate the immune response against cancer cells.

Used for several approved cancer indications.

May help control cancer progression.

Can be used alone or with chemotherapy/other immunotherapy.

Provides an established immunotherapy option for eligible patients.

Uses

Depending on local approvals, Durvalumab may be used for selected patients with:

Non-small cell lung cancer (NSCLC)

Small-cell lung cancer (SCLC)

Biliary tract cancer

Hepatocellular carcinoma

Certain other approved cancers

The appropriate use depends on the patient's diagnosis, cancer stage, previous treatment, and applicable guidelines.

Dosage & Administration

Durvalumab is given by intravenous infusion by trained healthcare professionals.

For several adult indications, a commonly used regimen is 1,500 mg every 4 weeks for patients weighing at least 30 kg. Other dosing schedules may apply depending on the cancer and treatment combination.

Patients should not change the dose or treatment schedule without their oncologist's advice.

Common Side Effects

Possible side effects include:

Fatigue

Cough

Shortness of breath

Rash

Diarrhea

Nausea

Reduced appetite

Muscle or joint pain

Fever

Infusion-related reactions

Serious Side Effects

Durvalumab may cause immune-related reactions affecting the lungs, liver, intestines, kidneys, thyroid, and other organs.

Seek medical attention for severe breathing problems, persistent diarrhea, abdominal pain, jaundice, serious rash, unusual weakness, or other concerning symptoms.

Durvalumab in india, USA, UK, UAE & Singapore

Durvalumab is a prescription oncology medicine. Availability, approved indications, import requirements, and treatment guidelines can differ between the India, USA, UK, UAE, and Singapore.

Hospitals, pharmacies, oncology centers, and healthcare providers should follow current local regulations and approved prescribing information.

FAQs

Is Durvalumab chemotherapy?

No. It is an immunotherapy and PD-L1 inhibitor, although it may be combined with chemotherapy.

How is Durvalumab administered?

It is given through IV infusion by qualified healthcare professionals.

What is the usual dose?

A commonly used adult regimen for several indications is 1,500 mg every 4 weeks, but the dose depends on the specific cancer and treatment protocol.

Can Durvalumab cause serious side effects?

Yes. It can cause immune-related inflammation involving different organs and requires medical monitoring.

Is Durvalumab available without a prescription?

No. It is a prescription cancer medicine and should be used under specialist medical supervision.

Medical Disclaimer

This content is for general educational purposes only and does not replace professional medical advice. Durvalumab should only be prescribed and administered by qualified healthcare professionals.